The GLP-1 receptor agonists are not a weight-loss story. They are an appetite-signaling story that happens, usefully, to be associated with weight loss. The distinction is not pedantic. It is the entire basis for whether the treatment goes well or poorly, and whether the body that emerges on the other side is stronger or weaker than the one that started.
Semaglutide and tirzepatide have moved from diabetes management into the mainstream executive-health conversation at unprecedented speed. The Bioneer’s position on the class is that it is a meaningful tool, over-prescribed in some contexts, under-supervised in others, and almost always delivered without the structural support that determines outcome quality. This piece is an attempt to say what the evidence actually shows, where the real risks sit, and what an honest protocol looks like for a member who decides to use them.
What is settled
On efficacy for weight loss in adults with obesity or overweight with comorbidity, the class is unambiguous. The STEP 1 trial (Wilding et al., NEJM 2021) showed mean 14.9 percent body-weight reduction with semaglutide 2.4 mg weekly over 68 weeks, compared with 2.4 percent on placebo. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed mean 20.9 percent body-weight reduction with tirzepatide 15 mg weekly over 72 weeks. These are the largest pharmacologic weight-loss effect sizes ever demonstrated in controlled trials of non-surgical interventions.
On cardiovascular outcomes, the SELECT trial (Lincoff et al., NEJM 2023) found a 20 percent reduction in major adverse cardiovascular events in overweight and obese patients without diabetes on semaglutide. The mechanism is not fully resolved — some of the benefit travels with weight loss, some appears to be weight-independent — but the signal is robust.
On tolerability, the class has real side effects (nausea, GI distress, delayed gastric emptying, rare pancreatitis, occasional gallbladder disease) but is broadly well-tolerated at initiated-and-titrated doses. The discontinuation rate in the trials is modest. The real-world compliance rate is worse, largely because patients are undertaught before starting.
What is open
Several things the public writing speaks of as settled are not.
Long-term safety beyond four years. The longest durable evidence on the current-generation GLP-1s runs to roughly four to five years in non-diabetic populations. The class mechanism has decades of diabetes-population experience, which is reassuring, but the specific long-term outcomes for the much larger non-diabetic cohort currently on these drugs are still accumulating.
Rebound weight trajectory. The STEP 4 extension showed that most of the weight lost on semaglutide was regained within a year of discontinuation. The structural question — whether people can use these drugs as a bridge to durable behavior change, or whether they function as lifelong therapy — is unresolved. Our clinical position is that it depends on what was built underneath the drug.
Lean mass preservation. The most consequential open question for the Bioneer audience. Lean body mass loss on GLP-1s, in non-resistance-trained populations, has been reported at 25 to 40 percent of total weight loss in several analyses. That figure is bad. It is also confounded by the populations studied, which are generally not training, not eating protein at adequate levels, and not supervised.
The lean-mass question, read carefully
The core mechanism of GLP-1 weight loss is appetite suppression — which produces caloric deficit, which produces weight loss from whatever tissues the body is most willing to part with. Without a training stimulus and adequate protein intake, those tissues include substantial skeletal muscle. The result is the now-familiar pattern: a patient who has lost 40 pounds, looks smaller and weaker, has lost strength and aerobic capacity, and will regain fat preferentially if the drug is stopped.
This is the failure mode the popular writing rarely describes. It is also the failure mode our protocol is most focused on preventing.
The interventions that protect lean mass during GLP-1 use are not mysterious. They are the same interventions that have always protected lean mass during caloric restriction: resistance training, performed at least twice weekly with progressive overload; protein intake at 1.0 to 1.2 grams per pound of target body weight, distributed across three to four feedings; and adequate sleep. What is different is that GLP-1 users often feel poorly enough in the initiation phase that they skip the training they would otherwise have done. The drug reduces the appetite for food and, without intention, the appetite for effort. That second effect is the one to plan against.
What our muscle-preserving protocol looks like
For members who are candidates for GLP-1 therapy and elect to use it under Dr. Chaudhari’s oversight, the protocol is structured rather than permissive:
- Baseline DEXA scan. Quantified lean mass and visceral fat before starting. We are not tracking scale weight alone; we are tracking composition.
- Resistance training, three times per week, non-negotiable. Compound lifts, progressive overload, attendance tracked. The members who stop showing up are the members who lose muscle.
- Protein intake at 1.0 to 1.2 g/lb target bodyweight. For most of our members this is 160 to 220 grams daily. On a GLP-1, this requires protein prioritization — eating protein first at every meal, because the appetite window closes before the meal is finished.
- Creatine monohydrate at 5 g daily. The most evidence-based adjunct for lean-mass preservation, and the one we recommend without ambiguity.
- HBOT and IV support where clinically indicated. Mitochondrial and recovery support during the adaptation period. Not a marketing add-on. Prescribed by indication.
- Quarterly DEXA follow-up. Not annual. Quarterly. We catch drift early.
- Physician check-in every eight weeks minimum. Labs, symptom review, dose adjustment, exit-ramp planning.
When the drug is right, and when it is not
Our clinical practice treats GLP-1s as indicated for patients with obesity (BMI ≥ 30) or overweight with metabolic comorbidity (BMI 27 to 30 with prediabetes, hypertension, dyslipidemia, or documented insulin resistance). For members with BMI below 27 and intact metabolic panels, the calculus is different: the evidence base is thinner, the cosmetic-adjacent use case is contested, and the muscle-mass risk rises because the deficit has less fat to draw on.
We decline to prescribe in that gray zone without an extended clinical conversation. The drug is not a vanity instrument. Members who want one should not be our members.
The exit ramp
The conversation we have the most, with members who have completed a successful GLP-1 cycle, is about what comes next. The two failure modes are symmetric: stopping abruptly and regaining, or staying on indefinitely as a dependency. The discipline we teach is planned tapering, structured over months, with training and nutrition capacity steadily built up to absorb the returning appetite. The goal is a body that can hold its new composition without the pharmacologic scaffolding — not forever, necessarily, but durably.
You are the kind of person who wants the drug to be an investment in the next decade of your metabolic health, rather than a treadmill you are now running. That distinction is architectural, not medical. It is built from the protocol underneath the prescription, and it is why our members who succeed on GLP-1s tend to be our members who were already training before they started.
— Published in The Bioneer, Journal. Reviewed by Dr. Swet Chaudhari, MD, Double Board-Certified Medical Director of Wellness Elite Fitness. This piece is informational; it is not medical advice. Consult your physician before beginning any new protocol.